ICER final evidence report on treatment for narcolepsy

The USA’s Institute for Clinical and Economic Review (ICER) released a Fina; Evidence Report assessing the comparative clinical effectiveness and value of oveporexton (TAK-861), from Japan’s Takeda Pharmaceutical (TYO: 4502) for narcolepsy type 1.

“The narcolepsy treatment landscape includes several pricey medications that do not provide complete relief for patients,” said the ICER’s senior vice president of research, Foluso Agboola, adding: “ICER’s analyses found that oveporexton, the first medication for narcolepsy type 1 that directly addresses the underlying cause of the condition, is effective in promoting wakefulness and improving quality of life, and appears to offer better health benefits than current options. The manufacturer choosing a value-based price for oveporexton would help de-escalate the cycle of high prices being met with onerous access challenges. Our independent analysis can offer a roadmap for improving affordability and access for patients and the health system.”